Bivalirudin in acute coronary syndromes.
Mattia GalliMarco BernardiLuis Ortega-PazRoberto NerlaDomenico D'AmarioFrancesco FranchiGiuseppe Biondi-ZoccaiDominick J AngiolilloPublished in: Expert review of cardiovascular therapy (2023)
In light of the increased understanding of the prognostic relevance of bleeding events and the excellent safety profile of bivalirudin, recent trial evidence may allow for this anticoagulant agent to reemerge and have a more prominent role in the management of ACS patients undergoing PCI.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- atrial fibrillation
- patients undergoing
- antiplatelet therapy
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery bypass grafting
- study protocol
- venous thromboembolism
- phase iii
- clinical trial
- coronary artery disease
- coronary artery bypass
- phase ii
- heart failure